Dosing JAK Inhibitors in Patients With Myelofibrosis

Opinion
Video

For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Related Content